DEC 2 7 2004 Under the Paperwork Reduction A

1617 W

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

TRANSMITTAL FORM

CO TRADERIO

1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number **Application Number** 09/765,491 Filing Date January 18, 2001 First Named Inventor Jack L. Arbiser Art Unit 1617 **Examiner Name** J. Kim Attorney Docket Number **EU 98055 CON**

(to be used for all correspondence after initial filing) Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Pabst Patent Group LLP Signature Tiffany B. Salmon Reg. No. 55 589	Am Ext Info Ce Do	Fee Attached Fee Attached After Final Affidavits/declaration(s) Affidav	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD Remarks		Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): 1 page of PTO-1449; two references; return postcard		
Firm Name Pabst Patent Group LLP Signature Printed name Tiffany B. Salmon				DNEY O	DACENT		
Printed name Pabst Patent Group LLP Signature Tiffany B. Salmon		SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Printed name Tiffany B. Salmon	Firm Name Pabst Patent Gro		oup LLP				
Tillarly B. Salinon	Signature Signature						
Date Reg. No. 55 589	Printed name Tiffany B. Salmon		n				
December 22, 2004	Date	December 22	_, 2004 Reg. No.		55,589		

CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature December 2 ද 200 Date Ronna Berman Typed or printed name

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/17 (12-04)

Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Action 1995, repersons are required to respond to a collection of information unless it displays a valid OMB control number

Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL For FY 2005

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

Complete if Known				
Application Number	09/765,491			
Filing Date	January 18, 2001			
First Named Inventor	Jack L. Arbiser			
Examiner Name	J. Kim			
Art Unit	1617			
Attorney Docket No.	EU 98055 CON			

METHOD OF PAYMENT (check all that apply)								
Check Credit Card Money Order None Other (please identify): Deposit Account Deposit Account Number: 50-3129 For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee								
UY under 37 CF WARNING: Information on th information and authorization	R 1.16 and 1 is form may be	.17 ecome public. Cre			it any overpay not be included		ovide credit care	i
FEE CALCULATION								
1. BASIC FILING, SEA	FILING		SEARCH	I FEES		TION FEES		:
Application Type	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	<u>Fee (\$)</u>	Fee (\$)	Fees Paid	1 (\$)
Utility	300	150	500	250	200	100		
Design	200	100	100	50	130	65		
Plant	200	100	300	150	160	80		
Reissue	300	150	500	250	600	300		
Provisional	200	100	0	0	0	0		
2. EXCESS CLAIM FEI Fee Description Each claim over 20 or, for Each independent claim Multiple dependent claim	or Reissues over 3 or, f						Fee (\$) 50	nall Entity Fee (\$) 25 100 180
Total Claims	Extra Cla <u>im</u>	s Fee (\$)	Fee Pai	d (\$)	Multiple De	ependent Clain		100
9 - 20 or HP =	0		_ =		Fee (\$)		aid (\$)	
HP = highest number of total Indep. Claims 3 - 3 or HP = HP = highest number of inder	Extra Claim 0	<u>Fee (\$)</u> _ x	Fee Paid	d (\$)	-			
3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$) 4. OTHER FEE(S) Fees Paid (\$)								
` ·	Non-English Specification, \$130 fee (no small entity discount)							
Other: Information	-	•	•				\$18	0.00

SUBMITTED BY			
Signature	Silles	Registration No. (Attorney/Agent) 55,589	Telephone (404) 879-2153
Name (Print/Type)	Tiffany B. Salmon		Date December 3. 2004

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Jack L. Arbiser

Serial No.:

09/765,491

Art Unit:

1617

Filed:

January 18, 2001

Examiner:

J. Kim

For:

CURCUMIN AND CURCUMINOID INHIBITION OF ANGIOGENSIS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicant submits a Supplemental Information Disclosure Statement, including 1 page of Form PTO-1449, and copies of the two (2) document(s) cited therein.

The Commissioner is hereby authorized to charge \$180.00 representing the fee required under 37 C.F.R. §1.17(p) for an Information Disclosure Statement filed after a first Office Action on the merits under 37 C.F.R. §1.97(c) to Deposit Account No. 50-3129. It is believed that no additional fees are required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-3129.

12/29/2004 RMEBRAHT 00000007 503129 09765491

01 FC:1806

180.00 DA

U.S.S.N.: 09/765,491

Filed: January 18, 2001

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

Publications

BOSMAN, "Testing of lipoxygenase inhibitors, cyclooxygenase inhibitors, drugs with immunomodulating properties and some reference antipsoriatic drugs in the modified mouse tail test, an animal model of psoriasis" *Skin Pharmacology* 7: 324-334 (1994).

"Curcumin Ointment" Internation Journal of Pharmaceutical Compounding 1(6): 409 (1997).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicant invites the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicant is of the opinion that his claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,

Tiffany B. Salmon

Reg. No. 55,589

Dated: December 22, 2004

PABST PATENT GROUP LLP 400 Colony Square, Suite 1200 1201 Peachtree Street Atlanta, Georgia 30361 (404) 879-2153 (Telephone) (404) 879-2160 (Fax)

The sale of the sa

2

45053164v1

	•	
	ě	
-		

_	Under the Pa	perwork Reduction	Act of 1995, r	no persons are required to respond to a colle	ction of information unless it contains a valid OMB	control number		
/() , , ,	Supstitute for			Complete if Known			
DE	TRADEN	STA		TION DISCLOSURE NT BY APPLICANT iny sheets as necessary)	Application Number	09765,491		
					Filing Date	January 18, 2001		
					First Named Inventor	Jack L. Arbiser		
					Group Art Unit	1617		
					Examiner Name	J. Kim		
	Sheet	1	of	1	Attorney Docket Number	EU 98055 CON		

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
xaminer's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	7
		BOSMAN, "Testing of lipoxygenase inhibitors, cyclooxygenase inhibitors, drugs with immunomodulating properties and some reference antipsoriatic drugs in the modified mouse tail test, an animal model of psoriasis" <i>Skin Pharmacology</i> 7: 324-334 (1994).	
		"Curcumin Ointment" Internation Journal of Pharmaceutical Compounding 1(6): 409 (1997).	
	•		
:			

	·		
Examiner's	Date Considered		
Signature			
	 		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.